Essential Hypertension
Conditions
Brief summary
The registry study aims to determine serial biomarkers to prognosis of Essential Hypertension
Detailed description
The study aims to investigate the role of candidate biomarkers in the prognosis of Essential Hypertension. In the prognosis part of the study, patients with confirmed hypertension are enrolled. The outcome is unstable angina, coronary revascularization, acute myocardial infarction, heart failure, atrial fibrillation, ischemic cerebral infarction, hemorrhagic cerebral infarction, transient ischemic attack, doubling of serum creatinine or end-stage renal disease (defi ned as eGFR less than 15 mL/min/1·73 m² or need for chronic dialysis) and all-cause mortality.
Interventions
None listed
Sponsors
Shanxi Medical University
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
The inclusion criteria for the study program were as follows: Men or women of any racial background, 18 years of age and older, with systolic BP greater than or equal to160 mm Hg, and presence of three or more cardiovascular risk factors or disease. The qualifying risk factors were male sex, age older than 50 years, verified diabetes mellitus, current smoking, high total cholesterol, left ventricular hypertrophy by electrocardiogram, proteinuria on dipstick and raised serum creatinine between 150 and 265 umol/L. The qualifying diseases were verified coronary disease, cerebrovascular disease or peripheral arterial occlusive disease, or left ventricular hypertrophy with strain pattern.
Exclusion criteria
The
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of cardiovascular adverse events | These data is collected from the cases' medical record or during follow-up visit at 1-3 years after discharge. | Number of cardiovascular adverse events including unstable angina, coronary revascularization, acute myocardial infarction, heart failure, atrial fibrillation. revascularization, myocardial infarction, heart failure |
| Number of cerebrovascular adverse events | These data is collected from the cases' medical record or during follow-up visit at 1-3 years after discharge. | Number of cerebrovascular adverse events including ischemic stroke and hemorrhagic stroke. |
| Number of renal adverse events | These data is collected from the cases' medical record or during follow-up visit at 1-3 years after discharge. | Number of renal adverse events including Double serum creatinine or end-stage renal disease (eGFR less than 15 mL/min/1.73 m2 or dialysis required). |
Countries
China
Contacts
Primary ContactYuan Wang, PhD
Backup ContactXin Tan, PhD
Outcome results
None listed